Imaging in cancer clinical trials will be the focus of a CME course to be jointly hosted by the Blinded Reader & Investigator Training Institute (BRITI) and the International Center for Postgraduate Medical Education (ICPME) on April 16 at the Doubletree Hotel, Philadelphia, Pa. The first CME course of its kind, the seminar will feature presentations by several pharmaceutical industry and academic experts, among them Wendy Hayes, DO (Bristol-Myers Squibb); David Raunig, PhD (Pfizer); Sanjay Saini, MD, MBA (Massachusetts General Hospital); James Conklin, MD (Pharma Imaging Group Consortium); and Andrew Buckler, MS (Buckler Biomedical, LLC). Additional speakers will be announced.
"We've designed this course for decision-makers in oncology drug development, clinical researchers and study personnel, as well as radiologists and oncologists using medical imaging to assess radiographic endpoints in the evaluation of drug efficacy. It provides attendees with a broad overview of imaging in cancer drug trials" says Rick Patt, MD, BRITI principal and course co-director. Specific topics to be covered in the course encompass an introduction to using imaging in cancer trials, risk management strategies when using imaging in cancer trials, biostatistical considerations and reader performance, and the blinded and site read processes. Quantitative imaging biomarkers, imaging efficacy evaluation criteria, and image standardization processes will be explored as well.
"With the increasing utilization of imaging in oncology trials has come a greater demand for formal training of pharmaceutical personnel on current concepts for applying imaging in drug trials,” asserts BRITI Principal and Course Co-Director Kohkan Shamsi, MD. “Regulatory agencies have also been placing greater emphasis on documented training of trial personnel. This course will provide attendees with practical and useable tools for using imaging in cancer drug trials.”
BRITI offers comprehensive education and training through a broad range of accredited CME courses in the area of medical imaging for pharmaceutical, medical device, and biotech clinical trials. For the past few years, it has partnered with ICPME to develop educational programs that are free of commercial bias.